1. Generics Bulletin
  3. >>Deals

Nichi-Iko And Eisai Expand Alliance To China

 
• By Dave Wallace

Nichi-Iko and Eisai have announced plans to build on their Japanese generics collaboration by expanding the partnership into China.

China
China Is The Next Step For The Japanese Collaboration • Source: Shutterstock

Nichi-Iko Pharmaceutical and Eisai are targeting China with the next phase of their collaboration, building on their existing partnership in Japan to take the next step of delivering Nichi-Iko’s generics to the Chinese market through Eisai’s marketing infrastructure.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.